Share on StockTwits

Research analysts at JPMorgan Chase & Co. began coverage on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) in a report released on Thursday, reports. The firm set an “overweight” rating and a $33.00 price target on the stock. JPMorgan Chase & Co.’s target price points to a potential upside of 74.88% from the stock’s previous close.

In other ACADIA Pharmaceuticals news, Director Torsten Rasmussen sold 32,857 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $20.03, for a total value of $658,125.71. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

A number of other analysts have also recently weighed in on ACAD. Analysts at Jefferies Group raised their price target on shares of ACADIA Pharmaceuticals from $26.00 to $38.00 in a research note on Tuesday, March 4th. Analysts at Zacks downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 27th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $27.29.

ACADIA Pharmaceuticals (NASDAQ:ACAD) traded up 1.38% on Thursday, hitting $19.13. The stock had a trading volume of 930,149 shares. ACADIA Pharmaceuticals has a 52 week low of $12.72 and a 52 week high of $32.00. The stock’s 50-day moving average is $20.45 and its 200-day moving average is $23.43. The company’s market cap is $1.893 billion. ACADIA Pharmaceuticals also saw a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 14,527,055 shares, a growth of 10.8% from the April 15th total of 13,111,252 shares. Based on an average daily volume of 2,141,032 shares, the days-to-cover ratio is currently 6.8 days. Approximately 14.9% of the company’s shares are short sold.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.19) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.13) by $0.06. Analysts expect that ACADIA Pharmaceuticals will post $-0.81 EPS for the current fiscal year.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.